Gastrointestinal cancer: Adjuvant chemotherapy after D2 gastrectomy for gastric cancer

Nature Reviews Clinical Oncology

Volumn 9, Issue 4, 2012, Pages 192-194

  Yoshikawa, Takaki ^a   Sasako, Mitsuru ^b  

^a KANAGAWA CANCER CENTER   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TAXANE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GASTRECTOMY; HUMAN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SHORT SURVEY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GASTRECTOMY; GASTROINTESTINAL NEOPLASMS; HUMANS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84859439102     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.23     Document Type: Short Survey

References (10)

1. Macdonald, J. S. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001).
2. Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11-20 (2006).
3. Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 29, 4387-4393 (2011).
4. Hundahl, S. A. et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann. Surg. Oncol. 9, 278-86 (2002).
5. Wu, C. W. et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 7, 309-315 (2006).
6. Okines, A. et al. Gastric Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v50-v54 (2010).
7. NCCN. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer Version 2.2011 [online], http://www.nccn.org/professionals/physician-gls/pdf/ gastric.pdf (2011).
8. Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315-321 (2012).
9. Macdonald, J. S. Gastric cancer: Nagoya is not New York. J. Clin. Oncol. 29, 4348-4350 (2011).
10. Lee, J. Y. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J. Clin. Oncol. 30, 268-273 (2012).